Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus
Part of paid clinical trials in Ann Arbor, Michigan.
- Sponsor
- University of Michigan Rogel Cancer Center
- Study ID
- NCT00239200
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Lapatinib — DRUG
Study Details
The purpose of this study is the determine whether a new compound, called lapatinib, can be effective in shrinking cancerous tumors of the esophagus that have recurred or spread somewhere else in the body. They also want to determine the toxicity of this regimen. Lapatinib blocks 2 receptors that sometimes are present on cancer cells (called epidermal growth factor receptor, and the Erb B2 receptor). It is possible that blocking these receptors may decrease the growth of the cancer cells.
Key Dates
- Start date
- Oct 31, 2005
- Status verified
- Jul 2008
- Primary completion
- Jun 30, 2006
- Completion
- Sep 30, 2007
Study Design
- Enrollment
- 29 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Primary Outcome:
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | - |